Aug 28, 2019
Research Conducted by the University of Birmingham Finds New Antimicrobial Coating Could be Key in Fight Against Hospital-Acquired Infections
Aug 12, 2019
Aridis Pharmaceuticals Announces Second Quarter 2019 Results
Aug 02, 2019
Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest(TM) BC kit
Jul 19, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Jun 27, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501
Jun 10, 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Jun 03, 2019
"Superbugs" Are No Match for the Advanced Penetration Technology(TM) Topical Platform
May 28, 2019
Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
May 14, 2019
Aridis Pharmaceuticals Announces First Quarter 2019 Results
Apr 11, 2019
Completion of the First Interventional Phase-II Trial in the Innovative Medicines Initiative's New Drugs 4 Bad Bugs Programme
Apr 01, 2019
Geom Therapeutics To Present Data From Antibiotic Drug Development Programs At ECCMID
Mar 28, 2019
Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
Mar 27, 2019
Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles
Feb 13, 2019
Public Health Notice - Information for Canadians who have received or are considering medical procedures in Mexico
Jan 03, 2019
VenatoRx Pharmaceuticals Joins Antimicrobials Working Group
Dec 13, 2018
Vast Therapeutics Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51
Dec 12, 2018
AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
Dec 04, 2018
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
Nov 13, 2018
Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview
Oct 25, 2018
Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis